July 26, 2017 5:32 AM ET

Commercial Services and Supplies

Company Overview of Cancer Research UK

Company Overview

Cancer Research UK is a charitable institution that supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The charity also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. The institute also operates an online portal CancerHelp UK that provides patient information. Cancer Research UK was incorporated in 2001 and is based in London, United Kingdom.

Angel Building

407 St. John Street

London,  EC1V 4AD

United Kingdom

Founded in 2001


44 20 7242 0200


44 20 3469 6400

Key Executives for Cancer Research UK

Chief Executive Officer and Chairman of the Executive Board
Chief Financial Officer
Compensation as of Fiscal Year 2017.

Cancer Research UK Key Developments

Cancer Research UK, Cancer Research Technology and Bicycle Therapeutics Collaborate to Trial New Therapy for Advanced Solid Tumours

Cancer Research UK, Cancer Research Technology (CRT), and Bicycle Therapeutics announced an agreement to trial a first-in-class drug for cancers of high unmet need. Cancer Research UK’s Centre for Drug Development (CDD) will sponsor and fund a Phase Ia and Phase Ib clinical trial for a drug called BT1718, a Bicycle Drug Conjugate® (BDC) being developed by Bicycle Therapeutics, in patients with advanced solid tumours. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MTP), which is highly expressed in many solid tumours, including triple negative breast cancer and non-small cell lung cancer. The trial will be co-managed by Cancer Research UK and Bicycle Therapeutics. Under the terms of the agreement, Bicycle retains the right to further advance the BT1718 programme, at which point an undisclosed payment split between cash and equity, success based milestones and royalty payments would be made to Cancer Research UK.

Cancer Research UK Enters into Joint Research Collaboration Agreement with Merck & Co and Verastem

Cancer Research UK has entered into joint research collaboration agreement with Merck & Co (US) and Verastem (US) to investigate the safety and efficacy of a combination immunotherapy to treat mesothelioma, non-small cell lung cancer (NSCLC), and pancreatic cancer. The Phase Ib/IIa trial will enrol 50-60 cancer patients and assess if Verastem's VS-6063 (defactinib), a focal adhesion kinase (FAK) inhibitor, can increase the effectiveness of Merck's PD-1 inhibitor Keytruda (pembrolizumab). The trial will be conducted at ECMC centres in Edinburgh-Dundee, Southampton, Glasgow, Leicester, and Belfast beginning some time between late 2016 and early 2017. It will be managed by Cancer Research UK and sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde. Preliminary studies by scientists at the University of Edinburgh demonstrated that FAK inhibition can enhance the cancer immune response and potentially increase the efficacy of PD-1 checkpoint inhibition. The Combinations Alliance was forged to help bring drug developers and researchers together to investigate new drug combinations that could improve outcomes for cancer patients. This is the first such deal bringing together two industry partners to look at potential treatments for mesothelioma, NSCLC, and pancreatic cancer, which all have very low survival rates (less than half) within a year of diagnosis in England and Wales.

Cancer Research UK Presents at BIO Trinity 2016, Apr-27-2016 02:35 PM

Cancer Research UK Presents at BIO Trinity 2016, Apr-27-2016 02:35 PM. Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom. Speakers: George Tzircotis, Snr Licensing Mgr, James Ritchie, Drug Dev Scientist.

Similar Private Companies By Industry

Company Name Region
"A T Promotions Limited Europe
1st Byte Print Limited Europe
1st Credit (Funding) Ltd Europe
1st Main Drain Ltd Europe
1st Option Safety Group Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cancer Research UK, please visit www.cancerresearchuk.org. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.